OBJECTIVE: To quantify the price that private payers pay hospitals for head and neck squamous cell carcinoma (HNSCC) treatments and identify hospital-level factors associated with price variation. STUDY DESIGN: Cross-sectional study. SETTING: Price transparency files. METHODS: Files from the top 50 hospitals in otolaryngology according to the US News and World Report were analyzed between December 2021 and June 2022. This study analyzed the following Food and Drug Administration-approved HNSCC therapies: pembrolizumab, nivolumab, cetuximab, cisplatin, carboplatin, and paclitaxel. RESULTS: Twenty-four (48%) hospitals reported prices for at least 1 medication in our sample. Newer biologics were significantly more expensive than traditional chemotherapeutic agents. Given approved medication regimens, all biologics in our sample have similar annual costs. Price markups over acquisition costs ranged between 109% (pembrolizumab, nivolumab) and 530% for carboplatin. Across hospitals, prices varied the most for paclitaxel, the cheapest medication in our sample, and prices varied the least for pembrolizumab the most expensive medication in our sample. Hospital 340B status and geographic location in the northeast/west are associated with lower price markups. CONCLUSION: Price nondisclosure remains a significant problem among hospitals. Newer biological medications are more expensive when compared to traditional chemotherapeutic agents. Prices vary significantly across hospitals, with lower price markups observed in 340B hospitals as well as hospitals located in the geographic northeast and west. It remains to be seen if price transparency will lead to more uniform pricing or lower costs of treatments.
Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6:92.
Egloff AM, Uppaluri R. Preoperative immunotherapy for head and neck cancers: state of art. Curr Opin Oncol. 2022;34:185-195.
Uppaluri R, Campbell KM, Egloff AM, et al. Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: a multicenter, phase II trial. Clin Cancer Res. 2020;26:5140-52.
Wise-Draper TM, Gulati S, Palackdharry S, et al. Phase II clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable local-regionally advanced head and neck squamous cell carcinoma. Clin Cancer Res. 2022;28:1345-1352.
Verma V, Sprave T, Haque W, et al. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. J Immunother Cancer. 2018;6:128.
Edmunds M, Sloan FA, eds. Committee on Geographic Adjustment Factors in Medicare Payment; Board on Health Care Services; Institute of Medicine. Geographic Adjustment in Medicare Payment: Phase I: Improving Accuracy. 2nd ed. National Academies Press; 2011.
Centers for Medicare & Medicaid Services. 2021 ASP drug pricing files. Accessed April 3, 2022. https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/2021-asp-drug-pricing-files
Centers for Medicare & Medicaid Services. 2023. Medicare part B drug average sales price. Accessed December 20, 2022. https://www.cms.gov/medicare/medicare-fee-for-service-part-b-drugs/mcrpartbdrugavgsalesprice
van de Schoot R, Broere JJ, Perryck KH, Zondervan-Zwijnenburg M, van Loey NE. Analyzing small data sets using Bayesian estimation: the case of posttraumatic stress symptoms following mechanical ventilation in burn survivors. Eur J Psychotraumatol. 2015;6:25216.
United States Census Bureau. QuickFacts. Accessed April 24, 2022. https://www.census.gov/quickfacts/fact/table/newyorkcitynewyork/POP010220
Health Resources and Services Administration. Covered Entity Search. Accessed June 11, 2022. https://340bopais.hrsa.gov/CoveredEntitySearch/000055977
U.S. Food and Drug Administration. Drugs@FDA: FDA-approved drugs. Accessed April 24, 2022. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
National Comprehensive Cancer Network. NCCN Guidelines. Accessed April 16, 2022. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1437
Ferris RL, Blumenschein G, Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856-1867.
Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394:1915-28.
R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2021. https://www.R-project.org/
Feldman WB, Rome BN, Brown BL, Kesselheim AS. Payer-specific negotiated prices for prescription drugs at top-performing US hospitals. JAMA Intern Med. 2021;182:83-86.
Wang AA, Rathi VK, Xiao R, et al. Private payer-negotiated prices for FDA-approved biologic treatments for allergic diseases. Int Forum Allergy Rhinol. 2021;12:798-801.
Xiao R, Rathi VK, Gross CP, Ross JS, Sethi RKV. Payer-negotiated prices in the diagnosis and management of thyroid cancer in 2021. JAMA. 2021;326:184.
Xiao R, Ross JS, Gross CP, et al. Hospital-administered cancer therapy prices for patients with private health insurance. JAMA Intern Med. 2022;182:603-611.
Chen BK, Yang YT, Bennett CL. Why biologics and biosimilars remain so expensive: despite two wins for biosimilars, the supreme court's recent rulings do not solve fundamental barriers to competition. Drugs. 2018;78:1777-81.
Tunis SR. Why Medicare has not established criteria for coverage decisions. N Engl J Med. 2004;350:2196-2198.
Roberts ET, Chernew ME, McWilliams JM. Market share matters: evidence of insurer and provider bargaining over prices. Health Aff. 2017;36:141-148.
Fisher MD, Punekar R, Yim YM, et al. Differences in health care use and costs among patients with cancer receiving intravenous chemotherapy in physician offices versus in hospital outpatient settings. J Oncol Pract. 2017;13:e37-e46.
Hannouf MB, Sehgal C, Cao JQ, Mocanu JD, Winquist E, Zaric GS. Cost-effectiveness of adding cetuximab to platinum-based chemotherapy for first-line treatment of recurrent or metastatic head and neck cancer. PLoS One. 2012;7:e38557.
Yeh J, Guddati AK. Cost-effectiveness analysis of nivolumab compared to pembrolizumab in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck. Am J Cancer Res. 2020;10:1821-1826.
Shah S, Reh G. Value-based payment models in oncology: will they help or hinder patient access to new treatments? Am J Manag Care. 2017;23:188.
Ji Y, Kong E. US hospital characteristics associated with price transparency regulation compliance. JAMA Health Forum. 2022;3:e221702.
